Payment overview · 2025
General Payments
$137.60
7 reported records · 6 companies
Healthcare provider profile · identity verified
Adam Waller, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · WEST FRANKFORT, IL · NPI 1508476615
Verified facts
What the public records show
CMS Open Payments records show Adam Waller, NP received $137.60 in general payments during 2025 across 7 reported records.
Lundbeck LLC accounted for 34.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lundbeck LLC | Unresolved — no canonical attribution shown | $46.71 | 34.0% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $25.27 | 18.4% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.72 | 14.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.55 | 13.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.40 | 10.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $12.95 | 9.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $137.60 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $66.43 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $25.27 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.55 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.40 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.40 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $12.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 309 | 59 |
| Lisinopril | Lisinopril | 301 | 49 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 296 | 52 |
| Amlodipine Besylate | Amlodipine Besylate | 215 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 185 | 17 |
| Levothyroxine Sodium | Levothyroxine Sodium | 183 | 29 |
| Potassium Chloride | Potassium Chloride | 176 | 27 |
| Gabapentin | Gabapentin | 170 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 167 | 14 |
| Eliquis | Apixaban | 155 | 21 |
| Omeprazole | Omeprazole | 155 | 29 |
| Donepezil Hcl | Donepezil Hcl | 147 | 20 |
| Metformin Hcl | Metformin Hcl | 147 | 28 |
| Tramadol Hcl | Tramadol Hcl | 135 | 32 |
| Furosemide | Furosemide | 130 | 27 |
| Lorazepam | Lorazepam | 125 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 124 | 41 |
| Fluticasone Propionate | Fluticasone Propionate | 115 | 36 |
| Trazodone Hcl | Trazodone Hcl | 115 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 112 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 111 | 16 |
| Losartan Potassium | Losartan Potassium | 104 | 18 |
| Sertraline Hcl | Sertraline Hcl | 103 | 15 |
| Montelukast Sodium | Montelukast Sodium | 98 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 95 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 94 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 94 | 57 |
| Memantine Hcl | Memantine Hcl | 93 | 13 |
| Alprazolam | Alprazolam | 87 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 86 | 15 |
| Mirtazapine | Mirtazapine | 85 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 83 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 81 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 80 | 11 |
| Famotidine | Famotidine | 77 | 14 |
| Carvedilol | Carvedilol | 76 | 18 |
| Clonazepam | Clonazepam | 74 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 72 | 14 |
| Prednisone | Prednisone | 67 | 40 |
| Jardiance | Empagliflozin | 66 | 11 |
| Simvastatin | Simvastatin | 65 | 12 |
| Buspirone Hcl | Buspirone Hcl | 64 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 63 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 60 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 54 | suppressed |
| Myrbetriq | Mirabegron | 51 | suppressed |
| Primidone | Primidone | 44 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 42 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 42 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 41 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 40 | suppressed |
| Levetiracetam | Levetiracetam | 40 | suppressed |
| Allopurinol | Allopurinol | 37 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 37 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 36 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 35 | suppressed |
| Lovastatin | Lovastatin | 34 | suppressed |
| Spironolactone | Spironolactone | 33 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Pregabalin | Pregabalin | 32 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 26 |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 24 |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Glimepiride | Glimepiride | 31 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 31 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 29 | suppressed |
| Aripiprazole | Aripiprazole | 29 | suppressed |
| Digoxin | Digoxin | 29 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 28 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Lidocaine | Lidocaine | 28 | suppressed |
| Meloxicam | Meloxicam | 28 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Cephalexin | Cephalexin | 26 | 15 |
| Morphine Sulfate Er | Morphine Sulfate | 26 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 24 | 23 |
| Celecoxib | Celecoxib | 24 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Ozempic | Semaglutide | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Lacosamide | Lacosamide | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Olanzapine | Olanzapine | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 15 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 13 |
| Rybelsus | Semaglutide | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 11 |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | 12 |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | 11 |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Elmiron | Pentosan Polysulfate Sodium | 11 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Roflumilast | Roflumilast | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $137.60 · 7 records | Lundbeck LLC | Auvelity, Cologuard Collection Kit, Ozempic, REXULTI, Rybelsus, VOQUEZNA | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error